David Warr

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Paul J. Hesketh, Steven M. Grunberg, Richard J. Gralla et al. · Journal of Clinical Oncology · 2003 · 770 citations

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

Mark N. Levine, V. Bramwell, Kathleen I. Pritchard et al. · Journal of Clinical Oncology · 1998 · 622 citations

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

Fausto Roila, Alex Molassiotis, Jørn Herrstedt et al. · Annals of Oncology · 2016 · 569 citations

Radiation Medicine, Radiation Therapy, Gastrointestinal Oncology +8

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

David Warr, Paul J. Hesketh, Richard J. Gralla et al. · Journal of Clinical Oncology · 2005 · 464 citations

Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer

David Osoba, Benny Zee, Joseph L. Pater et al. · Quality of Life Research · 1994 · 411 citations

Nursing, Quality Of Life, Life Assessment +9